最新发布第7页
排序
Crossover Study Highlights Pharmacokinetic Effects of DHE Powder STS101
A recently published, randomized, open-label, 5-period crossover study showed that treatment with STS101, an intranasal dihydroergotamine (DHE) powder, was safe in healthy particip...
11个月前
SAGE-324/BIIB124 Significantly Reduces Upper Limb Tremor in Phase 2 KINETIC Trial
Helen Colquhoun, MD(Credit: LinkedIn)Recently published in Movement Disorders, results from the double-blind, randomized, placebo-controlled, phase 2 KINETIC trial (NCT04305275) as...
11个月前
Cell-Based Therapies and Bembaneprocel
At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...
11个月前
Negative Myoclonus Associated With Severe Motor Implications in Progressive Myoclonus Ataxia
Marina A.J. Tijssen, MD, PhD(Credit: University of Groningen)In a newly published study in Movement Disorders, patients with progressive myoclonus ataxia (PMA) affected by negative...
11个月前Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN
WATCH TIME: 5 minutes'What I really wanted to highlight is that we should be thinking about equity, and access. Many solutions might have the ability to increase clinician efficien...
11个月前
ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS
Jeremy M. Shefner, MD, PhDNewly announced analyses from the phase 2b PARADIGM trial (NCT05357950) showed that treatment with PrimeC (NeuroSense), an investigational agent made up o...
11个月前
Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne
A patient in the phase 2 DALIGHT trial (NCT05429372) assessing Pfizer’s investigational gene therapy fordadistrogene movaparvovec (PF-06939926) in boys with Duchenne muscular dyst...
11个月前
